• Explore /
  • Poster
  • / A phase I/II study of nanoliposomal irinotecan and carboplatin in patients with advanced or metastatic, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma characterized by tissue and liquid next-generation sequencing.

A phase I/II study of nanoliposomal irinotecan and carboplatin in patients with advanced or metastatic, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma characterized by tissue and liquid next-generation sequencing.

Abstract Poster

Authors

null

Nai-Jung Chiang

Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Nai-Jung Chiang , Chien-Feng Li , Li-Yuan Bai , Chien-Jui Huang , Chih Chieh Yen , Chin-Fu Hsiao , Li-Ching Wu , Ming Huang Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Advanced Disease

Clinical Trial Registration Number

NCT05385861

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 52)

DOI

10.1200/JCO.2024.42.23_suppl.52

Abstract #

52

Poster Bd #

C4

Abstract Disclosures

Similar Posters

First Author: Erica Michelle Stringer

First Author: Patrick M Boland

First Author: Nely Mercy Diaz Mejia

First Author: Meng Xu WELLIVER